Relationships among medication adherence, insight, and neurocognition in chronic schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 69, Issue 5, 2015, Pages 298-304

  Na, Euihyeon ^a   Yim, Seon Jin ^a   Lee, Joon Noh ^a   Kim, Jung Min ^a   Hong, Kyungki ^a   Hong, Moon Hwa ^a   Han, Hyeree ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

insight; medication adherence; neurocognition; prognosis; schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; ATTITUDE TO ILLNESS; COGNITION; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTELLIGENCE; INTROSPECTION; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEUROCOGNITION; PATIENT COMPLIANCE; PROGNOSIS; RISK FACTOR; SCHIZOPHRENIA; SOUTH KOREA; TREATMENT REFUSAL; WORKING MEMORY; ATTITUDE TO HEALTH; CHRONIC DISEASE; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84928589195     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12272     Document Type: Article

References (44)

1. Sabaté E,. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization, Geneva, 2003.
2. Weiden PJ, Olfson M,. Cost of relapse in schizophrenia. Schizophr. Bull. 1995; 21: 419-429.
3. Sullivan G, Wells KB, Morgenstern H, Leake B,. Identifying modifiable risk factors for rehospitalization: A case-control study of seriously mentally ill persons in Mississippi. Am. J. Psychiatry 1995; 152: 1749-1756.
4. Kane JM,. Compliance issues in outpatient treatment. J. Clin. Psychopharmacol. 1985; 5: 22S-27S.
5. Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T,. Factors associated with medication non-adherence in patients suffering from schizophrenia: A cross-sectional study in a universal coverage health-care system. Aust. N. Z. J. Psychiatry 2010; 44: 921-928.
6. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F,. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr. Psychiatry 2008; 49: 170-176.
7. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009; 70: 1-46.
8. Masand PS, Narasimhan M,. Improving adherence to antipsychotic pharmacotherapy. Curr. Clin. Pharmacol. 2006; 1: 47-56.
9. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB,. Substance use: A powerful predictor of relapse in schizophrenia. Schizophr. Res. 1996; 20: 145-151.
10. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ,. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr. Serv. 2000; 51: 216-222.
11. Maeda K, Kasai K, Watanabe A, Henomatsu K, Rogers MA, Kato N,. Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia. Psychiatr. Serv. 2006; 57: 1203-1205.
12. American Psychiatric Association. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. American Psychiatric Association, Washington, DC, 2000.
13. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ,. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010; 167: 686-693.
14. Thompson K, Kulkarni J, Sergejew AA,. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr. Res. 2000; 42: 241-247.
15. Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr. Res. 2008; 100: 53-59.
16. Chang JG,. Insight and medication adherence in schizophrenia [PhD thesis]. Yonsei University, Seoul, 2013 (in Korean).
17. Sohail A, Ahmed S, Noman A, Candice WM,. Landing on the MARS. Br. J. Med. Pract 2012; 5: 9-13.
18. Song JY, Kim KT, Lee SK, et al. Reliability and validity of the Korean version of the Scale to Assess Unawareness of Mental Disorder (SUMD-K). J. Korean Neuropsychiatr. Assoc. 2006; 45: 307-315 (in Korean).
19. Kay SR, Fiszbein A, Opler LA,. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261-276.
20. Bae JN, Cho MJ,. Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. J. Psychosom. Res. 2004; 57: 297-305.
21. American Psychiatric Association. Global Assessment of Functioning Scale. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision American Psychiatric Association, Washington, DC, 2000.
22. Barch DM, Carter CS, Arnsten A, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: Proceedings of the third CNTRICS meeting. Schizophr. Bull. 2009; 35: 109-114.
23. Yeom Y, Park Y, Oh K, Kim J, Lee Y,. K-Wechsler Adult Intelligence Scale (K-WAIS). Korea Guidance, Inc., Seoul, 1992.
24. Kang Y, Na D,. Seoul Neuropsychological Screening Battery (SNSB). Human Brain Research & Consulting Co., Seoul, 2003.
25. Chey J, Lee J, Kim M, Kim H,. Development and standardization of the Elderly Verbal Learning Test (EVLT). Korean J. Psychol. Gen. 2006; 25: 141-173 (in Korean).
26. Loffler W, Kilian R, Toumi M, Angermeyer MC,. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-112.
27. Acosta FJ, Bosch E, Sarmiento G, Juanes N, Caballero-Hidalgo A, Mayans T,. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr. Res. 2009; 107: 213-217.
28. Keith SJ, Kane JM,. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J. Clin. Psychiatry 2003; 64: 1308-1315.
29. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV,. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003; 63: 49-58.
30. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry 2004; 65: 211-216.
31. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA,. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 2008; 69: 106-113.
32. Kemp R, David A,. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry 1996; 169: 444-450.
33. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA,. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002; 57: 209-219.
34. Morooka T, Ogino T, Takeuchi A, Kaoru H, Oka M, Ohtsuka Y,. Relationships between the color-word matching Stroop task and the Go/NoGo task: Toward multifaceted assessment of attention and inhibition abilities of children. Acta Med. Okayama 2012; 66: 377-386.
35. Harvey PD, Reichenberg A, Bowie C,. Cognition and aging in psychopathology: Focus on schizophrenia and depression. Annu. Rev. Clin. Psychol. 2006; 2: 389-409.
36. Liu-Seifert H, Osuntokun OO, Feldman PD,. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr. Psychiatry 2012; 53: 107-115.
37. Novak-Grubic V, Tavcar R,. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur. Psychiatry 2002; 17: 148-154.
38. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008; 371: 1085-1097.
39. Liu-Seifert H, Adams DH, Ascher-Svanum H, Faries DE, Kinon BJ,. Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer. Adherence 2007; 1: 9-17.
40. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 2004; 161: 692-699.
41. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV,. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J. Clin. Psychiatry 2002; 63: 892-909.
42. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR,. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J. Clin. Psychiatry 2006; 67: 1114-1123.
43. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: Relation between self-reports and serum level. J. Clin. Psychopharmacol. 2010; 30: 169-175.
44. Masand P, Roca M, Turner MS, Kane JM,. Partial adherence to antipsychotic medication impact is the course of illness in patients with schizophrenia: A review. Prim. Care Companion J. Clin. Psychiatry 2009; 11: 147-154.